Page 3 - Patrickj Haley News Today

Banco Santander S.A. purchased a new stake in Exelixis, Inc. (NASDAQ:EXEL – Free Report) during the 3rd quarter, Holdings Channel.com reports. The fund purchased 70,081 shares of the biotechnology company’s stock, valued at approximately $1,531,000. Other hedge funds also recently added to or reduced their stakes in the company. Fifth Third Bancorp increased its stake […]

Costello Asset Management INC lessened its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 43.0% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,920 shares of the biotechnology company’s stock after selling 2,205 shares during the period. Costello Asset Management INC’s […]

South Dakota Investment Council decreased its position in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 1.9% during the 3rd quarter, Holdings Channel reports. The firm owned 183,758 shares of the biotechnology company’s stock after selling 3,500 shares during the quarter. South Dakota Investment Council’s holdings in Exelixis were worth $4,015,000 at the end of the […]

Exelixis (NASDAQ:EXEL – Get Free Report) had its price objective upped by analysts at Barclays from $24.00 to $25.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s price target points to a potential upside of 14.21% from the stock’s current price. […]

Exelixis (NASDAQ:EXEL – Get Free Report) had its price objective boosted by research analysts at Barclays from $24.00 to $25.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s target price suggests a potential upside of 14.21% from the stock’s […]

Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) has been given an average rating of “Moderate Buy” by the eighteen research firms that are covering the stock, Marketbeat reports. Five analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 12-month price target among analysts […]

Los Angeles Capital Management LLC decreased its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 73.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 244,487 shares of the biotechnology company’s stock after selling 683,012 shares during the period. Los Angeles […]

Los Angeles Capital Management LLC lessened its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 73.6% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 244,487 shares of the biotechnology company’s stock after selling 683,012 shares during the quarter. Los Angeles Capital […]

LSV Asset Management lowered its position in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 18.1% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 1,037,640 shares of the biotechnology company’s stock after selling 229,835 shares during the period. LSV Asset Management owned 0.33% of Exelixis worth $22,672,000 […]

Exelixis, Inc. (NASDAQ:EXEL – Free Report) – Equities research analysts at William Blair upped their FY2023 earnings estimates for shares of Exelixis in a report issued on Monday, January 8th. William Blair analyst A. Hsieh now forecasts that the biotechnology company will post earnings of $0.58 per share for the year, up from their previous […]